Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease

Area of Science:

• Neonatology
• Pulmonology
• Pharmacology

Background:

• Neonatal chronic lung disease (CLD) is a significant complication in premature infants.
• Postnatal glucocorticoid therapy is a common treatment for CLD, showing acute pulmonary benefits.
• Earlier intervention with glucocorticoids (<14 days) may reduce mortality and CLD occurrence.

Purpose of the Study:

• To evaluate the benefits and risks of postnatal glucocorticoid therapy for neonatal CLD.
• To explore the potential of inhaled glucocorticoid therapy as a safer alternative to systemic administration.
• To identify areas for future research in optimizing CLD treatment.

Main Methods:

• Review of existing studies on postnatal glucocorticoid therapy for neonatal CLD.
• Analysis of data regarding early intervention, mortality, and CLD occurrence.
• Examination of adverse outcomes associated with glucocorticoid therapy.
• Assessment of emerging evidence on inhaled glucocorticoid therapy.

Main Results:

• Acute improvements in pulmonary status are observed with postnatal glucocorticoid therapy.
• Early intervention (<14 days) shows promise in reducing mortality and CLD.
• Significant concerns exist regarding adverse effects: growth inhibition, infection, GI complications, and CNS injury.
• Inhaled glucocorticoid therapy demonstrates potential for treating and preventing CLD with fewer systemic side effects.

Conclusions:

• The use of postnatal glucocorticoid therapy for neonatal CLD remains controversial due to the balance of benefits and risks.
• Inhaled glucocorticoid therapy offers a promising alternative, but requires optimization of aerosol delivery and deposition.
• Future research should focus on identifying high-risk infants and understanding CLD pathogenesis for personalized treatment strategies.